Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

NCT02735031 on ClinicalTrials.gov · last registry update 2018-04-12

A small phase 2/phase 3 — 10 participants, against a typical 60. The sponsor logged completion for 28 March 2018. Primary outcome, as filed: Symptom score in response to insulin-induced hypoglycaemia. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2/P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Radboud University Medical Center
Sponsor type: Other
Enrollment: 10
Started: 2017-02-21
Primary completion: 2018-03-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Symptom score in response to insulin-induced hypoglycaemia

Conditions studied

Diabetes Mellitus, Type 1 · Hypoglycemia

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.